Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Alnylam Pharmaceuticals, Inc. is one of them.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interference (RNAi) therapeutics, is advancing treatments for rare and prevalent diseases, notably transthyretin amyloidosis (ATTR). Its flagship product, Amvuttra (vutrisiran), treats both hereditary and cardiomyopathy forms of ATTR.

In Q2 2025, Amvuttra sales surged to $492 million, surpassing the $350 million consensus, driven by expanded use for ATTR cardiomyopathy approved in March 2025. Approximately 1,400 patients were on therapy by the end of the quarter. Strong performance prompted ALNY to raise its 2025 revenue guidance for Amvuttra and Onpattro to $2.18–$2.28 billion, with total projected net revenues between $2.65–$2.8 billion. This growth has lifted the company’s market valuation above $50 billion, with shares up over 15% recently.

Amvuttra’s quarterly subcutaneous administration may enhance patient adherence compared to oral competitors like Pfizer’s tafamidis and BridgeBio’s Attruby. Priced at $476,000 annually for cardiomyopathy, it is increasingly used as a first-line therapy, with commercial and Medicare payers approving treatment without prior competitor use, supporting sustainable growth in the U.S. market.

Beyond commercial success, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is advancing its pipeline, including RNAi therapeutics for cardiovascular disease, such as zilebesiran for hypertension. The business also presented 12-month HELIOS-B Phase 3 data showing sustained benefits of Amvuttra in ATTR cardiomyopathy. Additionally, ALNY joined the Alliance for Genomic Discovery in September 2025, leveraging large-scale genomic datasets to accelerate target discovery and innovation in gene silencing therapies.

While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.